Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | SVP, Chief Accounting Officer | September 15, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,863 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,283 · Balance 67,863 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 15, 2026 22:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,283 | $13.57 | $17,410.31 |
DisclosureSEC source: 0001193125-26-392233 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,863 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 16:29 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 161 | $13.99 | $2,252.39 |
DisclosureSEC source: 0001193125-26-384878 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,146 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 396 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,348 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001193125-26-177470 · ownership.xml · derivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,348 Underlying: Common Stock · 7,348 shares Expires 2036-04-22 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 20,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-177470 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,911 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,632 | $22.80 | $37,209.60 |
DisclosureSEC source: 0001193125-26-089109 · ownership.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,670 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 148 | $23.39 | $3,461.72 |
DisclosureSEC source: 0001193125-26-089109 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,302 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 18:49 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 85 | $34.38 | $2,922.30 |
DisclosureSEC source: 0001193125-25-336619 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,450 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 293 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2025. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 22:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 64 | $29.17 | $1,866.88 |
DisclosureSEC source: 0001193125-25-209387 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,242 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 18:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 84 | $31.39 | $2,636.76 |
DisclosureSEC source: 0000950170-25-113446 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,306 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 266 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 141 | $42.92 | $6,051.72 |
DisclosureSEC source: 0000950170-25-032764 · ownership.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,124 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 967 | $42.10 | $40,710.70 |
DisclosureSEC source: 0000950170-25-032764 · ownership.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,265 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,632 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-032764 · ownership.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,632 Underlying: Common Stock · 5,632 shares Expires 2035-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 9,392 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032764 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,232 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 23:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 648 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-135525 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,840 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F2 · balance_after: Includes 237 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2024. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 17:03 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107677 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,251 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 15:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 91 | $56.19 | $5,113.29 |
DisclosureSEC source: 0000950170-24-103807 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,551 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 276 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on April 30, 2024 F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 22:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 14 | $42.31 | $592.34 |
DisclosureSEC source: 0000950170-24-045670 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,366 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 2,351 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0000950170-24-026641 · ownership.xml · derivative · entry 5 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,351 Underlying: Common Stock · 2,351 shares Expires 2027-03-01 F6 · derivative.exercise_date: On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 8,200 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026641 · ownership.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2034-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 341 | $53.76 | $18,332.16 |
DisclosureSEC source: 0000950170-24-026641 · ownership.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,380 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 121 | $53.69 | $6,496.49 |
DisclosureSEC source: 0000950170-24-026641 · ownership.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,721 F2 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 13,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026641 · ownership.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,842 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000070 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 3,000 | $21.00 | $63,000.00 |
DisclosureSEC source: 0001209191-24-000070 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 20, 2023 Filed Jan 2, 2024 21:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000070 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,614 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 18:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 2,351 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-23-050841 · doc4.xml · derivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,351 Underlying: Common Stock · 2,351 shares Expires 2027-03-01 F2 · derivative.exercise_date: On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On September 27, 2023, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 784 shares on that date. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 17:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048905 · doc4.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 2,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 17:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 163 | $38.34 | $6,249.42 |
DisclosureSEC source: 0001209191-23-048905 · doc4.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,614 F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 17:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,000 | $41.00 | $82,000.00 |
DisclosureSEC source: 0001209191-23-048905 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,777 Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 17:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 2,000 | $21.00 | $42,000.00 |
DisclosureSEC source: 0001209191-23-048905 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 87 | $38.23 | $3,326.01 |
DisclosureSEC source: 0001209191-23-048489 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,777 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F3 · balance_after: The total amount of securities beneficially owned by the Reporting Person reflected in Table 1, Column 5 of this Form 4 reflects the correction of a typographical error in a previously filed Form 4 filed on April 18, 2023 ("April 2023 Form 4"). The corrected total amount of securities beneficially owned by the Reporting Person in Table 1, Column 5 of the April 2023 Form 4 is 21,520. The corrected total amount of securities beneficially owned by the Reported Person in Table 1, Column 5 of the Form 4 filed on behalf of the Reporting Person on May 10, 2023 is 24,747. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 883 | $37.04 | $32,706.32 |
DisclosureSEC source: 0001209191-23-048489 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,864 F1 · shares: The sale reported on this row of the Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Read SEC document |
| May 09, 2023 Filed May 11, 2023 00:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028585 · doc4.xml · derivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 3,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| May 09, 2023 Filed May 11, 2023 00:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 3,000 | $21.00 | $63,000.00 |
DisclosureSEC source: 0001209191-23-028585 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 227 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 16, 2023 Filed Apr 18, 2023 20:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Disposition to issuerCommon Stock | 181 | $38.20 | $6,914.20 |
DisclosureSEC source: 0001209191-23-024685 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,520 F2 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 16, 2023 Filed Apr 18, 2023 20:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 14 | $38.20 | $534.80 |
DisclosureSEC source: 0001209191-23-024685 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,701 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,120 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-23-016045 · doc4.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,120 Underlying: Common Stock · 10,120 shares Expires 2033-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Disposition to issuerCommon Stock | 1,333 | $45.65 | $60,851.45 |
DisclosureSEC source: 0001209191-23-016045 · doc4.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,715 F3 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 100 | $45.65 | $4,565.00 |
DisclosureSEC source: 0001209191-23-016045 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,048 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016045 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,148 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 19:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 639 | $43.40 | $27,732.60 |
DisclosureSEC source: 0001209191-23-014502 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,558 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 18:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,031 | $43.96 | $89,282.76 |
DisclosureSEC source: 0001209191-22-062400 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,197 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 134 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2022 F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 01, 2022 Filed Sep 8, 2022 22:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-049222 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,094 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes 180 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2022. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 16, 2022 Filed Apr 19, 2022 16:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 132 | $84.55 | $11,160.60 |
DisclosureSEC source: 0001209191-22-024699 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,914 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-22-015819 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Underlying: Common Stock · 7,400 shares Expires 2032-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015819 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,046 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F3 · balance_after: Includes 107 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 29, 2021. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 843 | $66.62 | $56,160.66 |
DisclosureSEC source: 0001209191-22-015819 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,229 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 22:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 140 | $81.14 | $11,359.60 |
DisclosureSEC source: 0001209191-21-060756 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,072 F1 · kind: Represents shares sold by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 13, 2021 Filed Oct 18, 2021 22:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 819 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060756 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,212 Read SEC document |
| May 06, 2021 Filed May 10, 2021 22:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 142 | $113.67 | $16,141.14 |
DisclosureSEC source: 0001209191-21-031386 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,031 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 129 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2021. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.